Key Features
- No footprint: Delivers drug without any polymer or additional coating. Low amount of paclitaxel left on site.
- Deep and homogeneous: Drug is homogeneously applied on the whole vessel surface in opposition to strut coating. Distal and proximal stent segments are optimally covered by pharmacotherapy.
- Atraumatic: Operates at low pressure
Concept
Indications
- Intra-Stent Restenosis: Apply antirestenotic drug homogeneously along the stent and its edges, without additional metallic material.
- Patients unfit for long-term anti-platelet therapy: 130 to 170 μg of Paclitaxel is sufficient to obtain desired results. Only about 2.9 to 3.7 μg of paclitaxel remain in the vessel wall. This reduces the need for long-term anti-platelet therapy, particularly appropriate for elderly people.
- Mutli-segment lesions: The same device can be used to treat several lesions in the same artery, during the same procedure. Ideal for the treatment of multi-segment lesions.
Technical Specifications
